Goodwin Investment Advisory’s AbbVie ABBV Stock Holding History

Goodwin Investment Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-385	Closed	-$62.2K	–	80
2022 Q4	$62.2K	Hold	385	–	–	0.04%	77
2022 Q3	$52K	Buy	+385	New	+$55.2K	0.04%	81
2022 Q2	–	Sell	-428	Closed	-$69K	–	169
2022 Q1	$69K	Buy	428 +328	+328%	+$47.6K	0.05%	68
2021 Q4	$14K	Buy	+100	New	+$11.8K	0.01%	116

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goodwin Investment Advisory's ABBV Position: Q1 2023 in Review

Goodwin Investment Advisory sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 385 shares — an estimated $62.2K sold.

Goodwin Investment Advisory first reported a position in ABBV in Q4 2021 and held it in 4 quarters. The position peaked at $69K in Q1 2022. 3,139 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

Goodwin Investment Advisory reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
Goodwin Investment Advisory sold 385 AbbVie shares in Q1 2023, an estimated $62.2K.
Goodwin Investment Advisory first reported a position in AbbVie in Q4 2021 and held it in 4 quarters.
Goodwin Investment Advisory's AbbVie position peaked at $69K in Q1 2022.
3,139 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Goodwin Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.